- Home
- SDOT vs IMRN Comparison
SDOT vs IMRN Comparison
Compare SDOT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDOT
- IMRN
- Stock Information
- Founded
- SDOT 2014
- IMRN 1994
- Country
- SDOT United States
- IMRN Australia
- Employees
- SDOT N/A
- IMRN N/A
- Industry
- SDOT Restaurants
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SDOT Consumer Discretionary
- IMRN Health Care
- Exchange
- SDOT Nasdaq
- IMRN Nasdaq
- Market Cap
- SDOT 8.0M
- IMRN 9.2M
- IPO Year
- SDOT 2020
- IMRN N/A
- Fundamental
- Price
- SDOT $1.08
- IMRN $1.72
- Analyst Decision
- SDOT
- IMRN Strong Buy
- Analyst Count
- SDOT 0
- IMRN 1
- Target Price
- SDOT N/A
- IMRN $5.00
- AVG Volume (30 Days)
- SDOT 567.0K
- IMRN 656.2K
- Earning Date
- SDOT 08-12-2025
- IMRN 09-08-2025
- Dividend Yield
- SDOT N/A
- IMRN N/A
- EPS Growth
- SDOT N/A
- IMRN N/A
- EPS
- SDOT 1.07
- IMRN N/A
- Revenue
- SDOT $726,598,000.00
- IMRN $4,048,286.00
- Revenue This Year
- SDOT $12.76
- IMRN N/A
- Revenue Next Year
- SDOT $5.54
- IMRN N/A
- P/E Ratio
- SDOT $0.89
- IMRN N/A
- Revenue Growth
- SDOT 18.91
- IMRN 82.90
- 52 Week Low
- SDOT $1.04
- IMRN $1.50
- 52 Week High
- SDOT $5.90
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- SDOT 39.19
- IMRN 45.31
- Support Level
- SDOT $1.04
- IMRN $1.60
- Resistance Level
- SDOT $2.30
- IMRN $1.80
- Average True Range (ATR)
- SDOT 0.14
- IMRN 0.10
- MACD
- SDOT -0.02
- IMRN -0.01
- Stochastic Oscillator
- SDOT 3.17
- IMRN 34.09
About SDOT Sadot Group Inc.
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.